Sanofi and its partner
Regeneron have secured significant drug approvals recently, including FDA approval for
Dupixent to treat chronic obstructive pulmonary disease (COPD), often referred to as 'smoker's lung'. This approval also extends to China, marking a dominant future presence for Dupixent in the COPD biologics market globally. Sanofi also secured FDA approval for
Sarclisa for myeloma treatment. In the arena of multiple sclerosis, Sanofi's drug
tolebrutinib reported a 31% delay in progressive MS in clinical trials. Sanofi is also making meaningful strides in its consumer health unit, drawing bids up to approximately $17 billion. It's also focusing on environmental responsibility, supporting decarbonization initiatives. Furthermore, Sanofi is experiencing growth in the radiopharma space with a $110M licensing deal, alongside a partnership with
AQEMIA harnessing AI for R&D. Additionally, Sanofi recently established a groundbreaking partnership with the
NAACP to advance health equity and also looks to invest significantly in India and Germany.
Sanofi News Analytics from Wed, 15 Nov 2023 13:59:02 GMT to Sun, 29 Sep 2024 15:00:16 GMT -
Rating 8
- Innovation 7
- Information 6
- Rumor -2
